首页 > 按月查看>2022年第4期 >30-34. DOI:10.11798/j.issn.1007-1520.202221291
PDF HTML 导出
慢性嗜酸性粒细胞型鼻窦炎的研究进展
作者:
基金项目:

国家自然科学基金（81541038，81670905，81870702）。


Research progress on chronic eosinophilic sinusitis
Author:
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • | |
    摘要:

    慢性嗜酸性粒细胞型鼻窦炎（ECRS）是以嗜酸性粒细胞浸润为特征的呼吸道黏膜炎性疾病。嗜酸性粒细胞是一种特殊的炎症细胞，与Th2型免疫反应密切相关。促进和维持ECRS患者嗜酸性炎症的机制主要有以下4个方面：白介素-5（IL-5）调控嗜酸性粒细胞的生物学效应、嗜酸性粒细胞胞外陷阱的免疫调节作用、细胞自噬调节和纤维蛋白异常沉积。ECRS表现出病因复杂、难治愈和易复发等特点，嗜酸性粒细胞在ECRS的发生发展中扮演着重要的角色。本文就国内外最新报道进行综述，以期为ECRS的治疗提供理论依据。

    Abstract:

    Eosinophilic chronic rhinosinusitis(ECRS) is an inflammatory disease of respiratory mucosa, which is characterized by eosinophil infiltration. Eosinophil is a special type of inflammatory cell, which is closely related to Th2 type immune response.There are four main mechanisms that promote and maintain eosinophilic inflammation in ECRS patients:the biological effects of interleukin-5 (IL-5) in regulating eosinophils, immunomodulatory effects of eosinophilic extracellular traps, autophagy regulation and abnormal fibrin deposition. ECRS is characterized by complex etiology, difficult cure and easy recurrence.Eosinophils play an important role in the occurrence and development of ECRS.This article reviews the latest reports at home and abroad in order to provide theoretical basis for the treatment of ECRS.

    网友评论
    网友评论
    分享到微博
    发 布
    参考文献
    [1] Fokkens W, Desrosiers M, Harvey R, et al.EPOS2020:development strategy and goals for the latest European Position Paper on Rhinosinusitis[J].Rhinology, 2019, 57(3):162-168.
    [2] 孙燕, 罗志强.嗜酸性粒细胞与慢性鼻-鼻窦炎伴鼻息肉的相关性研究进展[J].中国耳鼻咽喉颅底外科杂志, 2019, 25(1):104-108.
    [3] Bochner BS, Stevens WW.Biology and function of eosinophils in chronic rhinosinusitis with or without nasal polyps[J]. Allergy Asthma Immun, 2021, 13(1):8.
    [4] Grgić MV, ćupić H, Kalogjera L, et al.Surgical treatment for nasal polyposis:predictors of outcome[J].Eur Arch Otorhinolaryngol, 2015, 272(12):3735-3743.
    [5] Nakayama T, Yoshikawa M, Asaka D, et al.Mucosal eosinophilia and recurrence of nasal polyps-new classification of chronic rhinosinusitis[J].Rhinology, 2011, 49(4):392-396.
    [6] Lou H, Meng Y, Piao Y, et al.Cellular phenotyping of chronic rhinosinusitis with nasal polyps[J].Rhinology, 2016, 54(2):150-159.
    [7] Takatsu K.Interleukin-5 and IL-5 receptor in health and diseases[J].Proc Jpn Acad Ser B Phys Biol Sci, 2011, 87(8):463-485.
    [8] Nagase H, Ueki S, Fujieda S.The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases:Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis[J]. Allergol Int, 2020, 69(2):178-186.
    [9] Sarkis E, Patel S, Burns K, et al.Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia[J].J Asthma, 2020, 57(1):82-86.
    [10] Takatsu K, Nakajima H.IL-5 and eosinophilia[J].Curr Opin Immunol, 2008, 20(3):288-294.
    [11] Martinez-Moczygemba M, Huston DP, Lei JT.JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization[J].J Leukoc Biol, 2007, 81(4):1137-1148.
    [12] Kouro T, Takatsu K.IL-5-and eosinophil-mediated inflammation:from discovery to therapy[J].Int Immunol, 2009, 21(12):1303-1309.
    [13] Inoue H, Kato R, Fukuyama S, et al.Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness[J].J Exp Med, 2005, 201(1):73-82.
    [14] Sanmugalingham D, De Vries E, Gauntlett R, et al.Interleukin-5 enhances eosinophil adhesion to bronchial epithelial cells[J].Clin Exp Allergy, 2000, 30(2):255-263.
    [15] Angulo EL, McKernan EM, Fichtinger PS, et al. Comparison of IL-33 and IL-5 family mediated activation of human eosinophils[J].PLoS One, 2019, 14(9):e0217807.
    [16] Banerjee S, Biehl A, Gadina M, et al.Erratum to:JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases:Current and Future Prospects[J].Drugs, 2017, 77(11):1261.
    [17] Gross Atan.BCL-2 family proteins as regulators of mitochondria metabolism[J].Biochim Biophys Acta, 2016, 1857(8):1243-1246.
    [18] Mukherjee M, Lacy P, Ueki S.Eosinophil extracellular traps and inflammatory pathologies-Untangling the web![J]. Front Immunol, 2018, 9(undefined):2763.
    [19] Wartha F, Henriques-Normark B.ETosis:a novel cell death pathway[J].Sci Signal, 2008, 1(21):pe25.
    [20] Gevaert E, Zhang N, Krysko O, et al.Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation[J].J Allergy Clin Immunol, 2017, 139(6):1849-1860.
    [21] Gevaert E, Zhang N, Krysko O, et al.Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation[J].J Allergy Clin Immunol, 2017, 139(6):1849-1860.
    [22] Uribe Echevarría L, Leimgruber C, García González J, et al.Evidence of eosinophil extracellular trap cell death in COPD:does it represent the trigger that switches on the disease?[J].Int J Chron Obstruct Pulmon Dis, 2017, 12(undefined):885-896.
    [23] Hwang CS, Park SC, Cho HJ, et al.Eosinophil extracellular trap formation is closely associated with disease severity in chronic rhinosinusitis regardless of nasal polyp status[J].Sci Rep, 2019, 9(1):8061.
    [24] Liu JN, Suh DH, Trinh HK, et al.The role of autophagy in allergic inflammation:a new target for severe asthma[J].Exp Mol Med, 2016, 48(7):e243.
    [25] Hua W, Liu H, Xia LX, et al.Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice[J]. Respirology, 2015, 20(7):1055-1065.
    [26] Choi GE, Yoon SY, Kim JY, et al.Autophagy deficiency in myeloid cells exacerbates eosinophilic inflammation in chronic rhinosinusitis[J].J Allergy Clin Immunol, 2018, 141(3):938-950.
    [27] Wang LF, Chien CY, Yang YH, et al.Autophagy is deficient and inversely correlated with COX-2 expression in nasal polyps:a novel insight into the inflammation mechanism[J].Rhinology, 2015, 53(3):270-276.
    [28] Takabayashi T, Schleimer RP.Formation of nasal polyps:the roles of innate type 2 inflammation and deposition of fibrin[J].J Allergy Clin Immunol, 2020, 145(3):740-750.
    [29] Shimizu S, Ogawa T, Takezawa K, et al.Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp[J]. Am J Rhinol Allergy, 2015, 29(4):235-242.
    [30] Takabayashi T, Tanaka Y, Susuki D, et al.Increased expression of L-plastin in nasal polyp of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease[J].Allergy, 2019, 74(7):1307-1316.
    [31] Takabayashi T, Kato A, Peters AT, et al.Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression[J]. Am J Respir Crit Care Med, 2013, 187(1):49-57.
    [32] Bachert C, Han JK, Desrosiers M, et al.Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52):results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials[J].Lancet, 2019, 394(10209):1638-1650.
    [33] Lemarchant S, Docagne F, Emery E, et al.tPA in the injured central nervous system:different scenarios starring the same actor?[J].Neuropharmacology, 2012, 62(2):749-756.
    引证文献
引用本文

李凤珍,刘环海.慢性嗜酸性粒细胞型鼻窦炎的研究进展[J].中国耳鼻咽喉颅底外科杂志,2022,28(4):30-34

复制
分享
文章指标
  • 点击次数:318
  • 下载次数: 953
历史
  • 收稿日期:2021-08-01
  • 在线发布日期: 2022-09-03

中国耳鼻咽喉颅底外科杂志 ® 2025 版权所有 技术支持：北京勤云科技发展有限公司

温馨提示

本刊唯一投稿网址：www.xyosbs.com
唯一办公邮箱：xyent@126.com
编辑部联系电话：0731-84327210，84327469
本刊从未委托任何单位、个人及其他网站代理征稿及办理其他业务联系，谨防上当受骗！

关闭